Drug intelligence / Profile preview

InlaSel

Development stage: Preclinical
Lead developer: Villya Pharmaceuticals

Overview

InlaSel is an investigational drug candidate from Villya Pharmaceuticals being developed for the treatment of female genital schistosomiasis. Based on the provided context, InlaSel appears to be a specific named development program rather than a class of therapies, and patent approval was reported in 2021. Publicly available information in the supplied materials does not identify the active ingredient, molecular target, modality, dosage form, route of administration, or mechanism of action, so its pharmacology remains undisclosed from the available evidence.

Beyond the preview

Go deeper on InlaSel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InlaSel.

Explore the full profile